Ainslie Mitchell

Ainslie Mitchell

Auto-generated profile, based on publicly available information

Ainslie Mitchell

Infection Analytics Program, Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AHAlexandra Hogan
Alexandra Hogan
AMAinslie Mitchell
Ainslie Mitchell
ESEva Stadler
Eva Stadler
YCYuna Chung
Yuna Chung
ARArnold Reynaldi
Arnold Reynaldi
DCDeborah Cromer
Deborah Cromer
A number of vaccines and long-acting monoclonal antibodies have been shown to be effective in the prevention of respiratory syncytial virus (RSV) disease. However, an immune correlate of protection for RSV has not yet been identified. We conducted a systematic review to identify published reports of immunogenicity and/or efficacy in vaccines and long-acting monoclonal antibodies against RSV and performed a meta-analysis on extracted data to identify any relationship between antibody increase and protection against RSV disease. We identified 130 relevant reports which we classified into an open access evidence map of RSV immunisation products. We found a strong correlation between the immunisation induced rise in neutralising antibody titres and efficacy (ρ>0.7 for all comparisons, Spearman). For infants, we estimated that each 10-fold increase in neutralising antibody titre rise provides an additional 31% [95% CI 10%, 47%], 47% [95% CI 36%, 56%] and 57% [95% CI 45%, 66%] reduction in the relative risk of symptomatic, moderate and severe disease respectively. For older adults, a 10-fold rise in antibody levels was associated with a 34% [95% CI -2%, 57%], 50% [95% CI 22%, 67%] and 63% [95% CI 36%, 79%] reduction in the relative risk of RSV disease with 1, 2 and 3 symptoms respectively. These results align extremely well with findings from natural history studies and individual-based analysis of correlates of protection studies. This work paves the way for use of neutralising antibodies as a correlate of protection to guide the development, approval, and deployment of RSV vaccines and monoclonal antibodies.

5 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
KEKaren M Elias
Karen M Elias
EEEce Egilmezer
Ece Egilmezer
Shanchita R KhanShanchita R Khan
Shanchita R Khan
AMAinslie Mitchell
Ainslie Mitchell
ARArnold Reynaldi
Arnold Reynaldi
DKDavid S Khoury
David S Khoury
There is currently no clinical data for the effectiveness of the only licensed Ebola virus disease vaccine (Ervebo) against Bundibugyo virus disease. A number of studies have shown immune cross-reactivity with Bundibugyo virus after Ervebo vaccination. However, antibody recognition of Bundibugyo is around 2.8-fold lower than recognition of Ebola virus. Here, we aimed to infer how a 2.8-fold drop in immune recognition may affect Ervebo protection against Bundibugyo virus disease based on analysis of data on Ervebo immunogenicity and protection from Ebola virus disease. This work has three main components. Firstly, we analysed the timing of vaccine protection in the Ervebo pivotal ring vaccination clinical trial. Secondly, we performed a systematic review and meta-analysis of antibody responses to Ebola virus after Ervebo vaccination over time. Thirdly, we combined these data with previously reported data on the cross-reactivity to Bundibugyo virus to infer protection of Ervebo against Bundibugyo virus disease. We find that the clinical trial data for Ervebo supports vaccine protection beginning earlier than 10 days after vaccination. Secondly, binding antibody levels against Ebola virus on day 28 post vaccination (peak responses) were on average 12.9-fold (95% confidence interval, CI: 6.4 – 26.0) higher than on day 7, 6.3-fold (95% CI: 3.7 – 10.8) higher than on day 10, and 2.5-fold (95% CI: 1.4 – 4.4) higher than on day 14 (neutralising antibodies showed similar results). Finally, we consider the scenarios where antibody levels to Ebola virus at day 7 or 10 are putative protective thresholds against Ebola virus disease, and we assume these thresholds also apply for Bundibugyo virus disease. Then, with a 2.8-fold reduction of responses to Bundibugyo compared to Ebola virus, we predict antibody responses to Bundibugyo virus after Ervebo vaccination are likely above these putative protective thresholds.